论文部分内容阅读
5-羟色胺能神经系统与认知功能和摄食行为密切相关。目前研究人员正在对多种化合物进行生物评价,以确定其是否具有5-HT6受体拮抗作用。临床前研究结果表明,部分化合物对大鼠和人5-HT6受体具有较强的选择性拮抗作用,并能增强大鼠的认知功能,包括记忆保存与巩固,以及空间学习能力。因此,5-HT6受体拮抗剂在治疗神经精神疾病相关的认知损伤方面(如阿尔茨海默病、精神分裂症)较有前景。另外,这些化合物还有助于减少遗传型和饮食型肥胖者的食物摄入、脂肪吸收和体重增加。本文介绍了5-HT6受体拮抗剂用于治疗阿尔茨海默病和精神分裂症相关的认知功能障碍,以及肥胖症的研究进展。
The serotonergic nervous system is closely related to cognitive function and feeding behavior. Currently, many compounds are undergoing biological evaluation to determine whether they have 5-HT6 receptor antagonism. Preclinical studies have shown that some of these compounds have potent and selective antagonistic effects on rat and human 5-HT6 receptors and enhance cognitive function in rats, including memory preservation and consolidation, and spatial learning. Therefore, 5-HT6 receptor antagonists are more promising in the treatment of cognitive impairment associated with neuropsychiatric disorders such as Alzheimer’s disease and schizophrenia. In addition, these compounds also help reduce food intake, fat absorption and weight gain in genetically and diet-obese individuals. This article describes the 5-HT6 receptor antagonist for the treatment of Alzheimer’s disease and schizophrenia-related cognitive dysfunction, as well as the research progress of obesity.